Lehman Brothers Inc. (CNVX) E-mail or Print this story
31 March 2004, 11:25am ET
CNVX: Reit Overweight - CNVX is favorably positioned as a top cancer vaccine company, trading at a discount to its peers, that should benefit from increasing attention and validation for the class over the next 12 months Summary ! CNVX reported today encouraging results for its phase III melanoma vaccine Canvaxin from phase II trials in stage II melanoma. The data, presented at the American Association for Cancer Research (AACR) annual meeting suggested that pts treated with Canvaxin had extended survival when compared retrospectively to patients treated historically w/out CanVaxin (74 mo vs 44 mo 25th percentile survival) ! While retrospective analysis in phase II should be interpreted with some caution we are encouraged by attempts to minimize typical phase II bias in conducting a matched pair analysis which matches the 2 groups by key prognostic factors ! We continue to expect a strong partnership to be established for CanVaxin in 2004 and believe that CNVX should benefit from increasing visibility on cancer vaccines Click below to read more about subscribing to the full JAGnotes product.